Latest Hotspot

Innovent, Xuanzhu Launch Study on Sintilimab (PD-1 Inhibitor) and New ADC for Advanced Solid Tumors in China

5 January 2024
4 min read

Innovent Biologics, Inc., in partnership with Xuanzhu Biopharma, has publicly disclosed the initiation of a cooperative clinical trial and provision arrangement concerning the synergistic use of the medication sintilimab (marketed as TYVYT®) alongside KM-501, an innovative HER-2 targeted bispecific antibody-drug conjugate (ADC). This collaborative effort is aimed at exploring the efficacy of these combined therapies in addressing complex solid tumors within the Chinese medical landscape.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

As per the contract, Innovent is tasked with providing sintilimab for the joint clinical study. Xuanzhu Biopharma is set to carry out an initial Phase 1b clinical trial with the aim of assessing both the efficacy in combatting tumors and the safety profile of a co-therapy regimen consisting of sintilimab and KM-501 in a group of Chinese patients suffering from advanced solid tumors.

The compound TYVYT® (sintilimab injection) represents a groundbreaking inhibitor of PD-1, resulting from a joint development effort between Innovent and Eli Lilly and Company within the Chinese market. It has earned approval and has been incorporated into the national reimbursement drug list, covering a total of seven different uses. Notably, it is the exclusive PD-1 inhibitor indicated for primary line treatment in the case of five types of cancer with substantial incidence figures, as specified in the NRDL.

KM-501 has been developed using the Mebs-Ig platform that holds proprietary intellectual property rights and is an innovative dual-antibody ADC targeting two distinct HER2 domains. It has been deemed appropriate for combating advanced solid tumors, including metastatic growths, characterized by HER2 positivity/presence, amplified levels, or mutations. Its spectrum also extends to encompass advanced tumors that demonstrate low HER2 expression. The IND for this drug was sanctioned by the NMPA in March of the current year, and it is at present undergoing a Phase I dose-escalation research phase.

The combined use of a PD-1 inhibitor along with an ADC drug candidate is emerging as an exciting strategy in the field of cancer treatment, with potential implications for enhancing immunotherapy outcomes and addressing issues of drug resistance. By integrating PD-1-based immunotherapy, which can restore the reactivity of T cells, with an ADC that targets tumor cells with cytotoxic agents, the approach could foster a complementary effect that inhibits tumor growth more effectively.

Dr. Hui Zhou, who serves as a Senior Vice President at Innovent, remarked: "Engaging in this partnership with Xuanzhu Biopharma to study the cooperative anti-tumor effects deriving from the administered combined therapy of sintilimab and an innovative ADC candidate is gratifying. Such collaboration reinforces sintilimab's eminent role and the clinical significance it holds as a fundamental component in immunotherapy. Anticipating the combined modalities of these new drugs, our goal is to pioneer additional therapeutic pathways for individuals affected by cancer in the years ahead."

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of January 04, 2024, there are 324 investigational drugs for the PD-1 target, including 296 indications, 357 R&D institutions involved, with related clinical trials reaching 7669, and as many as 58090 patents.

Sintilimab has received approvals in China and globally for the treatment of various cancers and other diseases. The drug's targeting of PD-1 and its multiple regulatory designations highlight its potential as a breakthrough therapy in the field of biomedicine.

图形用户界面, 文本

描述已自动生成

What is the difference between passive and active drug delivery?
"What" Series
2 min read
What is the difference between passive and active drug delivery?
5 January 2024
Passive and active drug delivery are two distinct approaches used to improve the targeted delivery of drugs within the body.
Read →
What are endothelin receptor antagonists and how do you quickly get the latest development progress?
What are endothelin receptor antagonists and how do you quickly get the latest development progress?
5 January 2024
Endothelin receptor antagonists (ERAs) are drugs that block endothelin receptors, used to treat conditions like pulmonary arterial hypertension and Raynaud’s phenomenon.
Read →
What are drug interactions? What types of drug interactions are there?
"What" Series
2 min read
What are drug interactions? What types of drug interactions are there?
5 January 2024
Drug interactions occur when two or more medications are taken together and the effect is different than if they were taken separately.
Read →
Elpiscience and Astellas Pharma have formed a new R&D and licensing partnership to create innovative dual-targeting macrophage engagers
Latest Hotspot
3 min read
Elpiscience and Astellas Pharma have formed a new R&D and licensing partnership to create innovative dual-targeting macrophage engagers
5 January 2024
Elpiscience has partnered with Astellas Pharma through a fresh research and licensing deal to develop innovative dual-targeting macrophage engagers.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.